Literature DB >> 21109246

Prospective study of coronary heart disease vs. HDL2, HDL3, and other lipoproteins in Gofman's Livermore Cohort.

Paul T Williams1, Daniel E Feldman.   

Abstract

OBJECTIVE: To assess the relationship of lipoprotein subfractions to coronary heart disease (CHD).
METHODS: Prospective 29.1-year follow-up of 1905 men measured for lipoprotein mass concentrations by analytic ultracentrifugation between 1954 and 1957. Vital status was determined for 97.2% of the cohort. Blinded physician medical record and death certificate review confirmed 179 CHD deaths. Follow-up questionnaires identified 182 nonfatal myocardial infarctions and 93 revascularization procedures from 1346 (98.3%) of the surviving cohort and from the next-of-kin of 153 men who died.
RESULTS: When adjusted for age, total incident CHD was inversely related to HDL2-mass (P=0.0001) and HDL3-mass (P=0.02), and concordantly related to LDL-mass (P<10(-11)), IDL-mass (P<10(-7)), and small (P<10(-7)) and large VLDL-mass concentrations (P=0.003). The hazard reduction per mg/dl of HDL was greater for HDL2-mass than HDL3-mass (P=0.04). The lowest quartiles of both HDL2-mass (P=0.007) and HDL3-mass (P=0.001) independently predicted total incident CHD when adjusted for traditional risk factors. Risk for premature CHD (≤65 years old) was significantly greater in men within the lowest HDL2 (P=0.03) and HDL3 quartiles (P=0.04) and having higher LDL-mass concentrations (P=0.001). Serum cholesterol's relationship to incident CHD (P<10(-8)) was accounted for by adjustment for LDL-mass concentrations (adjusted P=0.90).
CONCLUSIONS: Lipoprotein subfractions differ in their relationship to CHD. Published by Elsevier Ireland Ltd.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21109246      PMCID: PMC3786414          DOI: 10.1016/j.atherosclerosis.2010.10.024

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  31 in total

1.  Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III).

Authors: 
Journal:  JAMA       Date:  2001-05-16       Impact factor: 56.272

2.  Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation.

Authors:  R B D'Agostino; S Grundy; L M Sullivan; P Wilson
Journal:  JAMA       Date:  2001-07-11       Impact factor: 56.272

3.  A comparison of simplified methods for lipoprotein quantification using the analytic ultracentrifuge as a standard.

Authors:  F T Lindgren; A Silvers; R Jutaglr; L Layshot; D D Bradley
Journal:  Lipids       Date:  1977-03       Impact factor: 1.880

4.  Visceral adiposity and incident coronary heart disease in Japanese-American men. The 10-year follow-up results of the Seattle Japanese-American Community Diabetes Study.

Authors:  W Y Fujimoto; R W Bergstrom; E J Boyko; K W Chen; D L Leonetti; L Newell-Morris; J B Shofer; P W Wahl
Journal:  Diabetes Care       Date:  1999-11       Impact factor: 19.112

5.  Analytic ultracentrifugation of plasma lipoproteins.

Authors:  T S Kahlon; L A Glines; F T Lindgren
Journal:  Methods Enzymol       Date:  1986       Impact factor: 1.600

6.  Ischemic heart disease, atherosclerosis, and longevity.

Authors:  J W Gofman; W Young; R Tandy
Journal:  Circulation       Date:  1966-10       Impact factor: 29.690

7.  Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: The Atherosclerosis Risk in Communities (ARIC) Study.

Authors:  A R Sharrett; C M Ballantyne; S A Coady; G Heiss; P D Sorlie; D Catellier; W Patsch
Journal:  Circulation       Date:  2001-09-04       Impact factor: 29.690

8.  Quantitation of serum lipoproteins by electrophoresis on agarose gel: standardization in lipoprotein concentration units (mg-100 ml) by comparison with analytical ultracentrifugation.

Authors:  S B Hulley; S G Cook; W S Wilson; M Z Nichaman; F T Hatch; F T Lindgren
Journal:  J Lipid Res       Date:  1971-07       Impact factor: 5.922

9.  Effects of therapy with cholestyramine on progression of coronary arteriosclerosis: results of the NHLBI Type II Coronary Intervention Study.

Authors:  J F Brensike; R I Levy; S F Kelsey; E R Passamani; J M Richardson; I K Loh; N J Stone; R F Aldrich; J W Battaglini; D J Moriarty
Journal:  Circulation       Date:  1984-02       Impact factor: 29.690

10.  Ion mobility analysis of lipoprotein subfractions identifies three independent axes of cardiovascular risk.

Authors:  Kiran Musunuru; Marju Orho-Melander; Michael P Caulfield; Shuguang Li; Wael A Salameh; Richard E Reitz; Göran Berglund; Bo Hedblad; Gunnar Engström; Paul T Williams; Sekar Kathiresan; Olle Melander; Ronald M Krauss
Journal:  Arterioscler Thromb Vasc Biol       Date:  2009-09-03       Impact factor: 8.311

View more
  36 in total

Review 1.  High-density lipoprotein and atherosclerosis: the role of antioxidant activity.

Authors:  Salman Bandeali; John Farmer
Journal:  Curr Atheroscler Rep       Date:  2012-04       Impact factor: 5.113

2.  Small Dense Low-Density Lipoprotein Cholesterol Predicts Cardiovascular Events in Liver Transplant Recipients.

Authors:  Mohammad Bilal Siddiqui; Tamoore Arshad; Samarth Patel; Emily Lee; Somaya Albhaisi; Arun J Sanyal; R Todd Stravitz; Carolyn Driscoll; Richard K Sterling; Trevor Reichman; Chandra Bhati; Mohammad Shadab Siddiqui
Journal:  Hepatology       Date:  2019-03-29       Impact factor: 17.425

Review 3.  Novel metabolic biomarkers of cardiovascular disease.

Authors:  Majken K Jensen; Monica L Bertoia; Leah E Cahill; Isha Agarwal; Eric B Rimm; Kenneth J Mukamal
Journal:  Nat Rev Endocrinol       Date:  2014-09-02       Impact factor: 43.330

Review 4.  Speciated High-Density Lipoprotein Biogenesis and Functionality.

Authors:  C Rosales; W S Davidson; B K Gillard; A M Gotto; H J Pownall
Journal:  Curr Atheroscler Rep       Date:  2016-05       Impact factor: 5.113

5.  Impact of obeticholic acid on the lipoprotein profile in patients with non-alcoholic steatohepatitis.

Authors:  Mohammad Shadab Siddiqui; Mark L Van Natta; Margery A Connelly; Raj Vuppalanchi; Brent A Neuschwander-Tetri; James Tonascia; Cynthia Guy; Rohit Loomba; Srinivasan Dasarathy; Julia Wattacheril; Naga Chalasani; Arun J Sanyal
Journal:  J Hepatol       Date:  2019-10-18       Impact factor: 25.083

Review 6.  New and emerging biomarkers in cardiovascular disease.

Authors:  Leah E Cahill; Monica L Bertoia; Sarah A Aroner; Kenneth J Mukamal; Majken K Jensen
Journal:  Curr Diab Rep       Date:  2015-11       Impact factor: 4.810

7.  Fifty-three year follow-up of coronary heart disease versus HDL2 and other lipoproteins in Gofman's Livermore Cohort.

Authors:  Paul T Williams
Journal:  J Lipid Res       Date:  2011-11-29       Impact factor: 5.922

Review 8.  From High-Density Lipoprotein Cholesterol to Measurements of Function: Prospects for the Development of Tests for High-Density Lipoprotein Functionality in Cardiovascular Disease.

Authors:  Frank M Sacks; Majken K Jensen
Journal:  Arterioscler Thromb Vasc Biol       Date:  2018-01-25       Impact factor: 8.311

9.  Severity of nonalcoholic fatty liver disease and progression to cirrhosis are associated with atherogenic lipoprotein profile.

Authors:  Mohammad S Siddiqui; Michael Fuchs; Michael O Idowu; Velimir A Luketic; Sherry Boyett; Carol Sargeant; Richard T Stravitz; Puneet Puri; Scott Matherly; Richard K Sterling; Melissa Contos; Arun J Sanyal
Journal:  Clin Gastroenterol Hepatol       Date:  2014-10-13       Impact factor: 11.382

Review 10.  Inflammation, lipid metabolism and cardiovascular risk in rheumatoid arthritis: A qualitative relationship?

Authors:  Carmen García-Gómez; Maria Bianchi; Diana de la Fuente; Lina Badimon; Teresa Padró; Emili Corbella; Xavier Pintó
Journal:  World J Orthop       Date:  2014-07-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.